CYCN
Price
$2.57
Change
-$0.19 (-6.88%)
Updated
Aug 27 closing price
Capitalization
8.84M
FATE
Price
$1.12
Change
+$0.01 (+0.90%)
Updated
Aug 27 closing price
Capitalization
129.17M
63 days until earnings call
Interact to see
Advertisement

CYCN vs FATE

Header iconCYCN vs FATE Comparison
Open Charts CYCN vs FATEBanner chart's image
Cyclerion Therapeutics
Price$2.57
Change-$0.19 (-6.88%)
Volume$36.92K
Capitalization8.84M
Fate Therapeutics
Price$1.12
Change+$0.01 (+0.90%)
Volume$1.01M
Capitalization129.17M
CYCN vs FATE Comparison Chart in %
Loading...
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYCN vs. FATE commentary
Aug 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYCN is a StrongBuy and FATE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 28, 2025
Stock price -- (CYCN: $2.57 vs. FATE: $1.12)
Brand notoriety: CYCN and FATE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYCN: 82% vs. FATE: 66%
Market capitalization -- CYCN: $8.84M vs. FATE: $129.17M
CYCN [@Biotechnology] is valued at $8.84M. FATE’s [@Biotechnology] market capitalization is $129.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $99.27B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYCN’s FA Score shows that 1 FA rating(s) are green whileFATE’s FA Score has 1 green FA rating(s).

  • CYCN’s FA Score: 1 green, 4 red.
  • FATE’s FA Score: 1 green, 4 red.
According to our system of comparison, both CYCN and FATE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYCN’s TA Score shows that 4 TA indicator(s) are bullish while FATE’s TA Score has 5 bullish TA indicator(s).

  • CYCN’s TA Score: 4 bullish, 7 bearish.
  • FATE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, FATE is a better buy in the short-term than CYCN.

Price Growth

CYCN (@Biotechnology) experienced а +7.98% price change this week, while FATE (@Biotechnology) price change was -0.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.04%. For the same industry, the average monthly price growth was +19.75%, and the average quarterly price growth was +30.54%.

Reported Earning Dates

FATE is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+4.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($129M) has a higher market cap than CYCN($8.84M). CYCN YTD gains are higher at: -20.186 vs. FATE (-32.121). CYCN has higher annual earnings (EBITDA): -3.76M vs. FATE (-161.6M). FATE has more cash in the bank: 223M vs. CYCN (3.01M). CYCN has less debt than FATE: CYCN (0) vs FATE (81.3M). FATE has higher revenues than CYCN: FATE (8.47M) vs CYCN (2.17M).
CYCNFATECYCN / FATE
Capitalization8.84M129M7%
EBITDA-3.76M-161.6M2%
Gain YTD-20.186-32.12163%
P/E RatioN/AN/A-
Revenue2.17M8.47M26%
Total Cash3.01M223M1%
Total Debt081.3M-
FUNDAMENTALS RATINGS
CYCN vs FATE: Fundamental Ratings
CYCN
FATE
OUTLOOK RATING
1..100
1865
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
8086
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (14) in the Biotechnology industry is in the same range as CYCN (16) in the null industry. This means that FATE’s stock grew similarly to CYCN’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CYCN (100) in the null industry. This means that FATE’s stock grew similarly to CYCN’s over the last 12 months.

CYCN's SMR Rating (95) in the null industry is in the same range as FATE (97) in the Biotechnology industry. This means that CYCN’s stock grew similarly to FATE’s over the last 12 months.

CYCN's Price Growth Rating (80) in the null industry is in the same range as FATE (86) in the Biotechnology industry. This means that CYCN’s stock grew similarly to FATE’s over the last 12 months.

CYCN's P/E Growth Rating (100) in the null industry is in the same range as FATE (100) in the Biotechnology industry. This means that CYCN’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYCNFATE
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 10 days ago
86%
Declines
ODDS (%)
Bearish Trend 17 days ago
89%
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 7 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
CYCN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RMRYF0.05N/A
+5.98%
ARMORY MNG CORP.
AATC7.450.05
+0.68%
Autoscope Technologies Corporation
PVARF10.00N/A
N/A
Porvair PLC
SVJTY21.90N/A
N/A
Severstal PAO
FLIDY6.07N/A
N/A
FLSmidth & Co. A/S

CYCN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYCN has been loosely correlated with HRTX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CYCN jumps, then HRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYCN
1D Price
Change %
CYCN100%
-6.88%
HRTX - CYCN
40%
Loosely correlated
-3.55%
GDTC - CYCN
30%
Poorly correlated
+2.03%
FATE - CYCN
29%
Poorly correlated
+0.90%
IBIO - CYCN
25%
Poorly correlated
+2.54%
PALI - CYCN
24%
Poorly correlated
-2.21%
More

FATE and

Correlation & Price change

A.I.dvisor indicates that over the last year, FATE has been loosely correlated with RXRX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if FATE jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FATE
1D Price
Change %
FATE100%
+0.90%
RXRX - FATE
54%
Loosely correlated
+1.24%
CRBU - FATE
53%
Loosely correlated
-1.00%
ALLO - FATE
53%
Loosely correlated
N/A
MGNX - FATE
51%
Loosely correlated
-4.97%
NTLA - FATE
50%
Loosely correlated
+0.53%
More